DOCSLIB.ORG

WDD License # Expiration Effective License Holder Name

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WDD License # Expiration Effective License Holder Name License Holder Name WDD License # Effective Expiration PATTERSON VETERINARY SUPPLY INC PHA-WDD-LIC-18941 12/21/2020 12/31/2021 MWI ANIMAL HEALTH PHA-WDD-LIC-1910 12/08/2020 12/31/2021 KVK-TECH INC PHA-WDD-LIC-2073 12/02/2020 12/31/2021 AMERISOURCEBERGEN DRUG CORPORATION PHA-WDD-LIC-1997 12/02/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2101 12/10/2020 12/31/2021 MYLAN PHARMACEUTICALS INC PHA-WDD-LIC-2204 12/02/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2177 12/10/2020 12/31/2021 FISHER CLINICAL SERVICES INC PHA-WDD-LIC-2150 12/03/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2120 12/10/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2216 12/10/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2169 12/10/2020 12/31/2021 TEVA PHARMACEUTICALS USA INC PHA-WDD-LIC-2198 12/10/2020 12/31/2021 CARDINAL HEALTH INC PHA-WDD-LIC-2166 12/02/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-40026 12/10/2020 12/31/2021 MWI ANIMAL HEALTH PHA-WDD-LIC-2348 12/08/2020 12/31/2021 DENVER SOLUTIONS LLC PHA-WDD-LIC-50894 12/14/2020 12/31/2021 FFF ENTERPRISES INC PHA-WDD-LIC-66517 12/07/2020 12/31/2021 COVETRUS NORTH AMERICA PHA-WDD-LIC-2798 12/04/2020 12/31/2021 SPECIALTY PHARMACEUTICAL SERVICES PHA-WDD-LIC-2323 12/02/2020 12/31/2021 AMERISOURCEBERGEN DRUG CORPORATION PHA-WDD-LIC-2887 12/02/2020 12/31/2021 J KNIPPER & COMPANY INC PHA-WDD-LIC-36466 12/22/2020 12/31/2021 COVETRUS NORTH AMERICA PHA-WDD-LIC-40300 12/04/2020 12/31/2021 PARMED PHARMACEUTICALS PHA-WDD-LIC-42684 12/02/2020 12/31/2021 BOUND TREE MEDICAL LLC PHA-WDD-LIC-2449 12/02/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2473 12/10/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-3283 12/10/2020 12/31/2021 KEYSOURCE ACQUISITION, LLC PHA-WDD-LIC-38556 12/14/2020 12/31/2021 TEVA PHARM USA INC PHA-WDD-LIC-186 12/10/2020 12/31/2021 PURDUE PHARMA LP PHA-WDD-LIC-3188 12/21/2020 12/31/2021 ALKERMES INC PHA-WDD-LIC-42930 12/02/2020 12/31/2021 ANIMAL HEALTH INTERNATIONAL, INC. PHA-WDD-LIC-35829 12/08/2020 12/31/2021 PATTERSON VETERINARY SUPPLY INC PHA-WDD-LIC-66712 12/16/2020 12/31/2021 WES PHARMA INC PHA-WDD-LIC-51619 12/03/2020 12/31/2021 ATLAS PHARMACEUTICALS PHA-WDD-LIC-51108 12/04/2020 12/31/2021 ANDA INC PHA-WDD-LIC-43109 12/07/2020 12/31/2021 CIVICA INC PHA-WDD-LIC-63176 12/07/2020 12/31/2021 THRIFTY WHITE WAREHOUSE #899 PHA-WDD-LIC-8703 12/02/2020 12/31/2021 MEDISCA INC PHA-WDD-LIC-470 12/03/2020 12/31/2021 HERITAGE PHARMACEUTICALS INC. PHA-WDD-LIC-55063 12/02/2020 12/31/2021 MICRO LABS USA INC PHA-WDD-LIC-57707 12/04/2020 12/31/2021 AMERISOURCEBERGEN DRUG CORPORATION PHA-WDD-LIC-42701 12/02/2020 12/31/2021 GOLDEN STATE MEDICAL SUPPLY INC PHA-WDD-LIC-50477 12/10/2020 12/31/2021 SOUTHERN ANESTHESIA & SURGICAL INC PHA-WDD-LIC-43212 12/02/2020 12/31/2021 ANIMAL HEALTH INTERNATIONAL INC PHA-WDD-LIC-53000 12/08/2020 12/31/2021 PRIORITY HEALTHCARE DISTRIBUTION INC PHA-WDD-LIC-42860 12/03/2020 12/31/2021 ANDERSON BRECON INC PHA-WDD-LIC-51099 12/02/2020 12/31/2021 PIRAMAL CRITICAL CARE INC PHA-WDD-LIC-43339 12/02/2020 12/31/2021 KEYSOURCE ACQUISITION, LLC PHA-WDD-LIC-66959 12/14/2020 12/31/2021 JEROME STEVENS PHARMACEUTICALS INC PHA-WDD-LIC-58511 12/10/2020 12/31/2021 PFIZER INC PHA-WDD-LIC-43125 12/15/2020 12/31/2021 ASD SPECIALTY HEALTHCARE LLC PHA-WDD-LIC-422 12/02/2020 12/31/2021 RICHIE PHARMACAL CO LLC PHA-WDD-LIC-1851 12/04/2020 12/31/2021 NUCARE PHARMACEUTICALS,INC. PHA-WDD-LIC-61814 12/11/2020 12/31/2021 NEPHRON SC INC PHA-WDD-LIC-42945 12/02/2020 12/31/2021 FAGRON PHA-WDD-LIC-8691 12/02/2020 12/31/2021 MCKESSON CORPORATION PHA-WDD-LIC-416 12/10/2020 12/31/2021 INDEPENDENT PHARMACY COOPERATIVE PHA-WDD-LIC-3198 12/03/2020 12/31/2021 MYLAN PHARMACEUTICALS INC PHA-WDD-LIC-1201 12/02/2020 12/31/2021 SPECIALTY PHARMACEUTICAL SERVICES PHA-WDD-LIC-2083 12/02/2020 12/31/2021 EPICUR PHARMACY PHA-WDD-LIC-52183 12/02/2020 12/31/2021 COVETRUS NORTH AMERICA PHA-WDD-LIC-2797 12/04/2020 12/31/2021 ACE SURGICAL SUPPLY CO INC PHA-WDD-LIC-2612 12/02/2020 12/31/2021 FRESENIUS KABI LLC PHA-WDD-LIC-51568 12/02/2020 12/31/2021 ASSOCIATED PHARMACIES INC PHA-WDD-LIC-2738 12/02/2020 12/31/2021 SCA PHARMACEUTICALS LLC PHA-WDD-LIC-41934 12/02/2020 12/31/2021 WELLGISTICS LLC PHA-WDD-LIC-62996 12/04/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-1258 12/10/2020 12/31/2021 FAGRON STERILE SERVICES LLC PHA-WDD-LIC-35537 12/04/2020 12/31/2021 TOP RX LLC PHA-WDD-LIC-28658 12/02/2020 12/31/2021 ACELRX PHARMACEUTICALS INC PHA-WDD-LIC-21351 12/07/2020 12/31/2021 INGENUS PHARMACEUTICALS LLC PHA-WDD-LIC-2909 12/22/2020 12/31/2021 JOM PHARMACEUTICAL SERVICES INC PHA-WDD-LIC-2334 12/04/2020 12/31/2021 ACTAVIS ELIZABETH LLC PHA-WDD-LIC-2014 12/10/2020 12/31/2021 PURDUE PHARMACEUTICALS LP PHA-WDD-LIC-2979 12/24/2020 12/31/2021 DIAMOND PHARMACY SERVICES PHA-WDD-LIC-1647 12/02/2020 12/31/2021 LUPIN PHARMACEUTICALS INC PHA-WDD-LIC-3058 12/02/2020 12/31/2021 STERRX LLC PHA-WDD-LIC-63306 12/10/2020 12/31/2021 MYLAN INSTITUTIONAL INC PHA-WDD-LIC-2879 12/02/2020 12/31/2021 HENRY SCHEIN INC PHA-WDD-LIC-2080 12/02/2020 12/31/2021 JOM PHARMACEUTICAL SERVICES INC PHA-WDD-LIC-2503 12/04/2020 12/31/2021 PADDOCK LABORATORIES LLC PHA-WDD-LIC-3086 12/17/2020 12/31/2021 HENRY SCHEIN INC PHA-WDD-LIC-2077 12/02/2020 12/31/2021 LETCO MEDICAL, LLC PHA-WDD-LIC-32575 12/02/2020 12/31/2021 B & B PHARMACEUTICALS INC PHA-WDD-LIC-41511 12/02/2020 12/31/2021 CARDINAL HEALTH PHA-WDD-LIC-2217 12/02/2020 12/31/2021 CURASCRIPT SD SPECIALTY DISTRIBUTION PHA-WDD-LIC-1949 12/03/2020 12/31/2021 MEDISCA INC PHA-WDD-LIC-34002 12/10/2020 12/31/2021 MCKESSON SPECIALTY CARE DISTRIBUTION LLC PHA-WDD-LIC-1987 12/11/2020 12/31/2021 HENRY SCHEIN INC PHA-WDD-LIC-2079 12/02/2020 12/31/2021 PAR STERILE PRODUCTS LLC PHA-WDD-LIC-26256 12/02/2020 12/31/2021 COVETRUS NORTH AMERICA PHA-WDD-LIC-11666 12/04/2020 12/31/2021 TEVA API INC PHA-WDD-LIC-28605 12/10/2020 12/31/2021 HENRY SCHEIN INC PHA-WDD-LIC-2078 12/02/2020 12/31/2021 CENTRAL ADMIXTURE PHARMACY SERVICES INC (CAPS) PHA-WDD-LIC-32453 12/04/2020 12/31/2021 EXPERT MED FIRST VETERINARY SUPPLY PHA-WDD-LIC-21817 12/02/2020 12/31/2021 PHARMACY BUYING ASSOCIATION PHA-WDD-LIC-2413 12/15/2020 12/31/2021 DAKOTA DRUG INC PHA-WDD-LIC-2151 12/18/2020 12/31/2021 THE HARVARD DRUG GROUP LLC PHA-WDD-LIC-32587 12/02/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-15231 12/10/2020 12/31/2021 MILLER VETERINARY SUPPLY PHA-WDD-LIC-71136 12/03/2020 12/31/2021 BOUND TREE MEDICAL LLC PHA-WDD-LIC-59678 12/02/2020 12/31/2021 MCKESSON CORPORATION PHA-WDD-LIC-59258 12/10/2020 12/31/2021 MWI ANIMAL HEALTH PHA-WDD-LIC-166 12/08/2020 12/31/2021 JEROME STEVENS PHARMACEUTICALS INC PHA-WDD-LIC-58510 12/10/2020 12/31/2021 PROF COMPOUNDING CTR OF AMERICA PHA-WDD-LIC-486 12/03/2020 12/31/2021 API RX PHA-WDD-LIC-12233 12/02/2020 12/31/2021 CARDINAL HEALTH 110 PHA-WDD-LIC-2378 12/02/2020 12/31/2021 JEROME STEVENS PHARMACEUTICALS INC PHA-WDD-LIC-58512 12/10/2020 12/31/2021 SEBELA PHARMACEUTICALS INC PHA-WDD-LIC-43032 12/02/2020 12/31/2021 SMITH DRUG COMPANY PHA-WDD-LIC-2902 12/02/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2214 12/10/2020 12/31/2021 SMITH DRUG COMPANY PHA-WDD-LIC-58821 12/02/2020 12/31/2021 SMITH DRUG COMPANY PHA-WDD-LIC-50564 12/02/2020 12/31/2021 AMERISOURCEBERGEN DRUG CORPORATION PHA-WDD-LIC-106 12/02/2020 12/31/2021 CARDINAL HEALTH 108, LLC PHA-WDD-LIC-66392 12/02/2020 12/31/2021 PAR PHARMACEUTICAL INC PHA-WDD-LIC-35260 12/02/2020 12/31/2021 PHARMACEUTICAL ASSOCIATES INC PHA-WDD-LIC-65899 12/02/2020 12/31/2021 GRANULES PHARMACEUTICALS INC PHA-WDD-LIC-42541 12/02/2020 12/31/2021 TAKEDA PHARMACEUTICALS AMERICA, INC. PHA-WDD-LIC-66892 12/02/2020 12/31/2021 AMERISOUCREBERGEN DRUG CORPORATION PHA-WDD-LIC-62905 12/03/2020 12/31/2021 AMERISOUCREBERGEN DRUG CORPORATION PHA-WDD-LIC-57588 12/03/2020 12/31/2021 AMERISOURCEBERGEN DRUG CORPORATION PHA-WDD-LIC-43153 12/02/2020 12/31/2021 AUBURN PHARMACEUTICAL COMPANY PHA-WDD-LIC-14211 12/02/2020 12/31/2021 PERRIGO PHARMACEUTICALS COMPANY PHA-WDD-LIC-12591 12/17/2020 12/31/2021 ANDA PHARMACEUTICALS INC PHA-WDD-LIC-42244 12/07/2020 12/31/2021 CLINICAL SOLUTIONS WHOLESALE, LLC PHA-WDD-LIC-56465 12/28/2020 12/31/2021 HENRY SCHEIN INC PHA-WDD-LIC-2081 12/02/2020 12/31/2021 J KNIPPER AND CO INC PHA-WDD-LIC-1395 12/22/2020 12/31/2021 CARDINAL HEALTH PHA-WDD-LIC-2713 12/02/2020 12/31/2021 CARDINAL HEALTH PHA-WDD-LIC-2740 12/02/2020 12/31/2021 FISHER CLINICAL SERVICES INC PHA-WDD-LIC-2971 12/03/2020 12/31/2021 EVERSANA LIFE SCIENCE SERVICES LLC PHA-WDD-LIC-58274 12/03/2020 12/31/2021 VISTAPHARM INC PHA-WDD-LIC-45826 12/04/2020 12/31/2021 EMERGENCY MEDICAL PRODUCTS INC PHA-WDD-LIC-14719 12/02/2020 12/31/2021 MCKESSON DRUG COMPANY PHA-WDD-LIC-2618 12/10/2020 12/31/2021.
Load more

Recommended publications
  • Alkermes Public Limited Company
    ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Year Ended March 31, 2013 ALKERMES PLC Table of Contents Page Directors’ Report .......................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ........................................... 59 Consolidated Statement of Comprehensive Income (Loss) ............................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 63 Consolidated Reconciliation of Shareholders’ Funds ................................. 62 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 111 Company Balance Sheet ..................................................... 113 Notes to the Company Financial Statements ....................................... 114 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the fiscal year ended March 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2009, which provides that a true and fair view of the state of
    [Show full text]
  • In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated
    Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 1 of 49 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS In re ALKERMES SECURITIES ) Master Docket No. 03-CV-12091-RCL LITIGATION ) ) CLASS ACTION This Document Relates To: ) ) ALL ACTIONS. ) ) ) CONSOLIDATED COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 2 of 49 SUMMARY AND OVERVIEW 1. This is a securities class action on behalf of all purchasers of the common stock of Alkermes, Inc. (“Alkermes” or the “Company”) between April 22, 1999 and July 1, 2002 (the “Class Period”), against Alkermes and certain of its officers and directors for violations of the Securities Exchange Act of 1934 (the “Exchange Act”). 2. Alkermes is a biopharmaceutical company focused on the development of controlled- release drug delivery technologies and their application to existing or new drug therapies. Among the drug delivery technologies defendants seek to develop are sustained-release systems based on biodegradable polymeric microspheres, including those based on Medisorb polymers. 3. In 1996, Alkermes entered into an agreement with JPI Pharmaceutical International (“Janssen”), an affiliate of pharmaceutical giant Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“Johnson & Johnson”), to develop an injectable form of the schizophrenic drug Risperdal, based upon the Medisorb polymer technology, called Risperdal Consta. Janssen has marketed the oral form of Risperdal since 1993, with sales of $2.3 billion in 2003. According to a December 12, 2001 report by analysts Thomas Weisel Partners, LLC (“Thomas Weisel”), during the Class Period, oral Risperdal was the most prescribed drug in the $5.3 billion atypical antipsychotic market.
    [Show full text]
  • Explanation of Conflict of Interest Disclosure Parts: Part One: All
    Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present) Part Two: Income Sources & Equity of $10,000 or greater Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present): Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present) Part Five: My primary employer is a pharmaceutical/biotech/medical device company. 2012 Program Committee Disclosures Anissa Abi-Dargham: Part 1: Pfizer; Otsuka; Takeda; Sunovion; Shire; Roche; Pierre Favre; Part 2: Pierre Favre William Carlezon: Part 1: Referring to 2010-2011: Scientific Advisory Board, Myneurolab.com; Consultant, Concert Pharmaceuticals; Consultant, Lantheus Medical Imaging; Consultant, Transcept Pharmaceuticals, (Spouse) Senior Scientist, EMD Serono; Part 2: (Spouse) Senior Scientist, EMD Serono, Part 3: (Spouse) Senior Scientist, EMD Serono Cameron Carter: Part1: GlaxoSmithKline research; Part 4: GlaxoSmithKline Karl Deisseroth: Part
    [Show full text]
  • Corporate Responsibility Report
    Corporate Responsibility Report October 2019 ©2019 Alkermes. All rights reserved. Table of Contents Section 1: Introduction . 2 Section 2: About Our Company . 3 Section 3: Our Approach to Corporate Responsibility . 4 Section 4: Environment . 6 Section 5: Social . 15 Section 6: Governance . 23 Section 7: The Future of Corporate Responsibility at Alkermes and About This Report . 27 ALKERMES • CORPORATE RESPONSIBILITY REPORT 1 SECTION 1 INTRODUCTION A Message from Our CEO Alkermes was founded by pioneers in the field of Inspired by the courage and determination of individuals neuroscience, and their legacy of innovation and in these frequently underserved and marginalized scientific excellence — applied to the real-world needs communities, we are driven to develop medicines and of patients — remains central to our mission. Alkermes contribute to systemic solutions that we hope will have technologies and discoveries have contributed to a meaningful impact on the lives of patients. important medicines that continue to shape the treatment landscape in many disease areas. Today, Our Commitment we are distinguished from other biopharmaceutical As we look toward building our business for the companies by our core focus on serious mental illness future, we are guided by the opportunity — and what and addiction — chronic, highly prevalent conditions we believe is our responsibility — to help address the that affect millions of people and represent some of unmet needs of patients and to operate in a sustainable, the most challenging public health issues of our time. socially responsible manner. We firmly believe that doing so is best for our business, our employees, for Great science. Deep compassion.
    [Show full text]
  • Commercial Products
    Website www.alkermes.com Ticker Symbol (NASDAQ) ALKS Alkermes, Inc. is a fully integrated biotechnology company that develops medicines designed to yield better outcomes Contacts and improve patients’ lives. Our products, which use novel molecules and innovative drug technologies, target Rebecca Peterson Vice President, Corporate widespread diseases including central nervous system (CNS) disorders, addiction and diabetes. We approach the drug Communications development process from a patient-centric perspective, beginning with a thorough understanding of the challenges Voice: 617-583-6378 patients face on a day-to-day basis. Our products are designed with patient needs and behaviors in mind, with the goal Blair Jackson of ensuring that patients consistently take their medication for long-term treatment success. Vice President, Business Development Alkermes has multiple partnered programs and also works independently to develop and commercialize proprietary Voice: 617-250-1594 products. The company has built a wide range of capabilities, including innovative research programs, clinical development, large-scale manufacturing, and a commercial presence in the marketplace. Corporate Headquarters Alkermes, Inc. 88 Sidney Street Cambridge, MA 02139 VIVITROL® Voice: 617-494-0171 Commercial Products (naltrexone for extended-release injectable suspension) Fax: 617-494-9263 RISPERDAL® CONSTA® [(risperidone) long-acting injection] Product: VIVITROL is an injectable formulation of naltrexone, based on Alkermes’ unique Medisorb Product: RISPERDAL CONSTA is a long-acting injectable technology. VIVITROL is designed for once-monthly form of Johnson & Johnson’s schizophrenia drug, dosing, eliminating the need for patients to make a RISPERDAL. Developed utilizing Alkermes’ proprietary daily decision about taking their medicine. Alkermes Medisorb® technology, RISPERDAL CONSTA is manufactures VIVITROL at its commercial facility in Ohio administered once every two weeks, rather than daily, and markets the product independently in the U.S.
    [Show full text]
  • Signatory Companies
    PhRMA Direct to Consumer Advertising Principles Signatory Companies In October 2018, the PhRMA BoArd of Directors Adopted meAsures to enhAnce the PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines. The revised, voluntAry Principles become effective on April 15, 2019. The revised, voluntAry Principles include A new guiding principle stAting thAt “[A]ll DTC television Advertising thAt identifies A prescription medicine by nAme should include direction as to where patients can find information about the cost of the medicine, such as a company- developed website, including the list price And Average, estimAted or typicAl pAtient out-of- pockets costs, or other context About the potentiAl cost of the medicine.” The Principles Also stAte thAt PhRMA will identify on its website All compAnies thAt voluntArily And independently commit to Abide by the Principles And will identify compAnies thAt complete, At the AppropriAte time, AnnuAl certificAtions thAt they hAve policies And procedures in plAce to foster compliAnce with the Principles. The following is A list of All signAtory compAnies who hAve Announced thAt they intend to Abide by the Principles: AbbVie GlAxoSmithKline Alexion Pharmaceuticals, Inc. Incyte CorporAtion Alkermes plc. Ipsen BiophArmAceuticAls, Inc. Allergan plc Johnson & Johnson Amgen Inc. Lundbeck Inc. Astellas Americas Merck & Co., Inc. AstrAZenecA PhArmAceuticAls LP NovArtis PhArmAceuticAls CorporAtion Bayer CorporAtion Novo Nordisk Inc. Biogen OtsukA AmericA PhArmAceuticAl, Inc. (OAPI) BioMArin PhArmAceuticAl Inc. Pfizer Inc Boehringer Ingelheim PharmAceuticAls, Inc. Purdue PhArmA L.P. Bristol-Myers Squibb CompAny Sanofi Celgene CorporAtion Sunovion Pharmaceuticals Inc. Daiichi SAnkyo, Inc. TakedA PhArmAceuticAls USA, Inc. EisAi Inc. TevA PhArmAceuticAls Eli Lilly And CompAny UCB EMD Serono .
    [Show full text]
  • Schedule 14A Schedule 14A Information
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: ☑ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a- 6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § Rule 14a-12 ALKERMES PLC (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☑ No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: NOT APPLICABLE (2) Aggregate number of securities to which transaction applies: NOT APPLICABLE (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): NOT APPLICABLE (4) Proposed maximum aggregate value of transaction: NOT APPLICABLE (5) Total fee paid: NOT APPLICABLE o Fee paid previously with preliminary materials: NOT APPLICABLE o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Oral Presentation Disclosures
    Oral Presentation Disclosures Adler, Lenard – Alcobra Pharma, APSARD/Pond Foundation, Major League Baseball, Major League Baseball Players Association, National Football League, New York University School of Medicine, Novartis Bioventures, Shire Pharmaceuticals, Sunovion, SUNY Upstate, Theravance, US Department of Veterans Affairs Cooperative Studies Program Anton, Raymond – Abbvie, Alkermes, Eli Lilly, Ethypharm, Lundbeck, Pfizer, Sunpharma Baker, Ross – Otsuka Pharmaceutical Development & Commercialization, Inc. Baldwin, David – Lundbeck Beaver, Jessica – Targacept, Inc. Bencherif, Merouane – Targacept, Inc. Bertolino, Alessandro – F. Hoffmann-La Roche, Ltd. Bradshaw, Mark – Euthymics Bioscience, Neurovance, Inc. Burdick, Katherine – Dainippon Sumitomo Pharma Bymaster, Frank – Euthymics Bioscience, Neurovance, Inc. Calabrese, Joseph – Sunovion, Teva (Cephalon) Cantillon, Marc – Forest, Kyowa, Lilly, Merck, Pfizer, Reviva Caroff, Stanley – Sunovion Chen, Yinzhong – Takeda Development Center Americas, Inc. Chengappa, Roy – Pfizer, Inc. Childress, Ann – Abbott Laboratories, Bristol Myer Squibb, GlaxoSmithKline, Ironshore, Janssen (Ortho-McNeil), Johnson & Johnson PRD, Lilly, Neos Therapeutics, Neurovance Inc., NextWave, Novartis, Noven, Otsuka, Pfizer, Rhodes, Sepracor, Shionogi, Shire, Somerset, Sunovion, Theravance Christine, Mazzucco – Janssen Cohen, Lee – Astra-Zeneca Pharmaceuticals, Bristol-Myers Squibb, Cephalon, Inc., GlaxoSmithKline, National Institute of Mental Health, National Institute on Aging, Noven Pharmaceuticals, Ortho-McNeil
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1032470 (State or other jurisdiction of (I.R.S. Employer Identification incorporation or organization) No.) Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4, Ireland 011-353-1-634-7800 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on Title of each class which registered Ordinary shares, nominal The NASDAQ Stock Market value $0.0001 per share LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Alkermes Public Limited Company
    Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents The information in this prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This prospectus supplement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of such securities in any jurisdiction in which such offer solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction. PRELIMINARY PROSPECTUS SUPPLEMENT (SUBJECT TO COMPLETION), DATED MARCH 7, 2012 PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(3) To Prospectus Dated March 7, 2012 Registration No. 333-179550 13,900,000 Ordinary Shares ALKERMES PUBLIC LIMITED COMPANY Ordinary Shares The selling shareholder is offering 13,900,000 ordinary shares. The selling shareholder will receive all net proceeds from the sale of our ordinary shares in this offering. Our ordinary shares are listed on the NASDAQ Global Select Stock Market (the "NASDAQ") under the symbol ALKS. On March 6, 2012, the last sale price of the ordinary shares on the NASDAQ was $17.25 per share. Investing in the ordinary shares involves risks. See "Risk Factors" beginning on page 10 of the accompanying prospectus. Per Share Total Public offering price Underwriting discount Proceeds to the selling shareholder (before expenses) The selling shareholder has granted the underwriters the right to purchase up to an additional 2,085,000 ordinary shares.
    [Show full text]
  • Medical Affairs Pharmd Fellowship
    Medical Affairs PharmD Fellowship 2018 - 2020 Alkermes plc is a fully At Alkermes plc, our employees consistently strive to provide physicians and patients with integrated, global bio- treatment options that address important unmet needs. Through our scientific expertise, pharmaceutical company proprietary technologies and global resources, we are uniquely positioned to continue building a portfolio of medicines for major clinical conditions with a focus on central nervous system focused on developing (CNS) disorders. innovative medicines that address the unmet Our success to date is evident from our diverse commercial product portfolio, including treatments in major diseases, such as schizophrenia, addiction, diabetes and multiple needs and challenges sclerosis. Beyond our commercial products, we have a promising pipeline of proprietary of people living with drug candidates, many in late-stage development. Both our commercialized products and serious, chronic diseases. rich pipeline demonstrate our leadership in drug development for CNS diseases, a therapeutic area where we have established expertise and a promise for delivering new treatments. Our Proprietary Products Products Using Alkermes Technologies Our commercial product portfolio reflects We have granted licenses under our proprietary technologies WEBSITE www.alkermes.com our years of experience in developing to enable third parties to develop, commercialize and, in TICKER SYMBOL innovative and patient-inspired solutions. some cases, manufacture products for which we receive NASDAQ: ALKS These unique products address patient royalties and/or manufacturing revenues. HEADQUARTERS needs in major disease areas. ® Connaught House AMPYRA (dalfampridine) is a twice-daily, controlled- 1 Burlington Road ARISTADA® (aripiprazole lauroxil) extended- release tablet indicated as a treatment to improve walking Dublin 4, Ireland release injectable suspension is indicated in patients with multiple sclerosis.
    [Show full text]
  • Aripiprazole Lauroxil Nanocrystal Suspension
    Out of the Pipeline Aripiprazole lauroxil nanocrystal suspension Jonathan M. Meyer, MD New long- ong-acting injectable (LAI) antipsychot- Table 1 acting injectable ics were developed due to the pervasive Fast facts about aripiprazole formulation Lproblem of oral medication nonad- lauroxil nanocrystal suspension herence among patients with severe mental simplifies the Brand name: Aristada Initio illnesses. While use of LAI antipsychotics initiation regimen reduces hospitalization rates, one issue in Class: Long-acting injectable atypical antipsychotic (aripiprazole) transitioning patients to certain LAI prepa- Indication: Adults with schizophrenia rations is the need for prolonged oral cover- Approval date: June 29, 2018 age when beginning treatment with agents that cannot be loaded.1,2 Nonadherence with Availability date: August 1, 2018 this bridging oral therapy places the patient Manufacturer: Alkermes, Inc., Waltham, MA at risk for symptom exacerbation until effec- Dosing forms: 675 mg IM injection tive antipsychotic plasma levels are achieved Recommended dosage for schizophrenia: 1 After establishing oral aripiprazole tolerability, from the LAI. To obviate the need for 3 weeks administer 675 mg IM along with a single of oral medication coverage when commenc- 30 mg oral aripiprazole dose at the time of ing treatment with aripiprazole lauroxil (AL; initiating aripiprazole lauroxil maintenance treatment. The maintenance dose of Aristada), a new LAI form of AL was devel- aripiprazole lauroxil should be given at the oped utilizing smaller
    [Show full text]